MoonLake Immunotherapeutics [MLTX] stock is trading at $46.88, down -0.49%. An important factor to consider is whether the stock is rising or falling in short-term value. The MLTX shares have gain 6.62% over the last week, with a monthly amount drifted -9.64%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
MoonLake Immunotherapeutics [NASDAQ: MLTX] stock has seen the most recent analyst activity on January 17, 2025, when Goldman upgraded its rating to a Buy and also boosted its price target to $82 from $62. On August 26, 2024, downgrade downgraded it’s rating to Peer Perform. Oppenheimer started tracking the stock assigning a Outperform rating and suggested a price target of $104 on June 25, 2024. Goldman initiated its recommendation with a Neutral and recommended $62 as its price target on April 02, 2024. Wolfe Research started tracking with a Outperform rating for this stock on February 15, 2024, and assigned it a price target of $77. In a note dated December 08, 2023, Citigroup initiated an Buy rating and provided a target price of $72 on this stock.
MoonLake Immunotherapeutics [MLTX] stock has fluctuated between $37.55 and $64.98 over the past year. Currently, Wall Street analysts expect the stock to reach $79.33 within the next 12 months. MoonLake Immunotherapeutics [NASDAQ: MLTX] shares were valued at $46.88 at the most recent close of the market. An investor can expect a potential return of 69.22% based on the average MLTX price forecast.
Analyzing the MLTX fundamentals
Gross Profit Margin for this corporation currently stands at -1.75% with Operating Profit Margin at -5499.02%, Pretax Profit Margin comes in at -4177.26%, and Net Profit Margin reading is -4092.01%. To continue investigating profitability, this company’s Return on Assets is posted at -0.16, Equity is -0.16 and Total Capital is -0.22. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 45.42 points at the first support level, and at 43.97 for the second support level. However, for the 1st resistance point, the stock is sitting at 48.17, and for the 2nd resistance point, it is at 49.46.
Ratios To Look Out For
For context, MoonLake Immunotherapeutics’s Current Ratio is 25.51. On the other hand, the Quick Ratio is 25.51, and the Cash Ratio is 18.71.
Transactions by insiders
Recent insider trading involved BVF PARTNERS L P/IL, Director, that happened on Oct 04 ’24 when 2.0 million shares were sold. Director, Sturge Simon completed a deal on Oct 04 ’24 to sell 0.17 million shares. Meanwhile, Chief Executive Officer Santos da Silva Jorge sold 62810.0 shares on Feb 27 ’24.
